Show simple item record

dc.contributor.authorCardona, Andres
dc.contributor.authorRojas, Leonardo
dc.contributor.authorWills, Beatriz
dc.contributor.authorBernal, Laura
dc.contributor.authorRuiz-Patiño, Alejandro
dc.contributor.authorArrieta, Oscar
dc.contributor.authorJiménez Hakim, Enrique
dc.contributor.authorHakim, Fernando
dc.contributor.authorMejía, Juan Armando
dc.contributor.authorUseche, Nicolás
dc.contributor.authorBermúdez, Sonia
dc.contributor.authorCarranza, Hernán
dc.contributor.authorVargas, Carlos
dc.contributor.authorOtero, Jorge
dc.contributor.authorMayor, Luis Carlos
dc.contributor.authorOrtíz, León Darío
dc.contributor.authorFranco, Sandra
dc.contributor.authorOrtíz, Carlos
dc.contributor.authorGil-Gil, Miguel
dc.contributor.authorBalaña, Carmen
dc.contributor.authorZatarain-Barrón, Zyanya Lucia
dc.date.accessioned2020-05-18T06:04:54Z
dc.date.available2020-05-18T06:04:54Z
dc.identifier.issn1573-7373spa
dc.identifier.urihttp://hdl.handle.net/20.500.12495/2900
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherSpringerspa
dc.relation.ispartofseriesJournal of Neuro-Oncology, 1573-7373, Vol 136, Num 2, 2018, pag 363-371spa
dc.relation.urihttps://link.springer.com/article/10.1007/s11060-017-2660-0spa
dc.titleEfficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastomaspa
dc.typearticlespa
dc.type.localartículospa
dc.subject.decsAnticonvulsivantesspa
dc.subject.decsEvaluación de medicamentosspa
dc.subject.decsPirrolidinonasspa
dc.subject.keywordsEfficacyspa
dc.subject.keywordsSafetyspa
dc.subject.keywordsAntiepileptic drugsspa
dc.subject.keywordsHispanicspa
dc.subject.keywordsGlioblastomaspa
dc.identifier.doihttps://doi.org/10.1007/s11060-017-2660-0spa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.publisher.journalJournal of Neuro-Oncologyspa
dc.title.translatedEfficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastomaspa
dc.description.abstractenglishEpilepsy is a common symptom in patients with glioblastoma (GB). 213 patients with GB from RedLANO follow-up registry were included. All patients underwent surgery, if feasible, followed by chemoradiation based on temozolomide (Stupp platform). Information was recorded regarding demographics, seizure timing, anti-epileptic drugs (AEDs), dosage, time to next seizure, total seizures in 6 months, and main side effects of AEDs. The relationship between epilepsy treatment and overall survival (OS) was evaluated. Mean age was 53 years old and 56.8% were male. Seventy-eight patients (37%) were treated with levetiracetam (LEV), 27% were given another AED and 36% did not require any AED. Choice of AED was not associated with age (p = 0.67), performance status (p = 0.24) or anatomic tumor site (p = 0.34). Seizures and AED requirement were greater in those having primary GB (p = 0.04). After starting an AED, the mean time until next crisis was 9.9 days (SD ± 6.3), which was shorter in those receiving LEV (p = 0.03); mean number of seizures during the first 3 and 6 months were 2.9 and 4, respectively. Most patients treated with LEV (n = 46) required less than two medication adjustments compared to those treated with other AEDs (p = 0.02). Likewise, less patients exposed to LEV required a coadjuvant drug (p = 0.04). Additionally, patients receiving LEV had significantly less adverse effects compared to patients treated with another AED. OS was significantly higher in the group treated with LEV compared to other AEDs (25.5 vs. 17.9 months; p = 0.047). Patients treated with LEV had better seizure control and longer OS compared to other AEDs.spa
dc.rights.localAcceso cerradospa
dc.date.issued2018


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record